Rocket Pharmaceuticals Inc’s recently made public that its insider Militello John unloaded Company’s shares for reported $15978.0 on Nov 21 ’24. In the deal valued at $13.05 per share,1,224 shares were sold. As a result of this transaction, Militello John now holds 49,310 shares worth roughly $0.51 million.
Then, Patel Kinnari sold 4,588 shares, generating $59,892 in total proceeds. Upon selling the shares at $13.05, the insider now owns 392,395 shares.
Before that, Shah Gaurav sold 11,091 shares. Rocket Pharmaceuticals Inc shares valued at $144,782 were divested by the CEO at a price of $13.05 per share. As a result of the transaction, Shah Gaurav now holds 707,328 shares, worth roughly $7.38 million.
Wedbush initiated its Rocket Pharmaceuticals Inc [RCKT] rating to an Outperform in a research note published on December 30, 2024; the price target was $32. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. Scotiabank began covering RCKT with “Sector outperform” recommendation on October 16, 2024. Goldman started covering the stock on April 02, 2024. It rated RCKT as “a Neutral”.
Price Performance Review of RCKT
On Tuesday, Rocket Pharmaceuticals Inc [NASDAQ:RCKT] saw its stock fall -2.80% to $10.43. Over the last five days, the stock has lost -15.55%. Rocket Pharmaceuticals Inc shares have fallen nearly -17.02% since the year began. Nevertheless, the stocks have fallen -63.25% over the past one year. While a 52-week high of $31.47 was reached on 01/02/25, a 52-week low of $10.28 was recorded on 01/13/25. SMA at 50 days reached $13.58, while 200 days put it at $19.21.
Levels Of Support And Resistance For RCKT Stock
The 24-hour chart illustrates a support level at 10.19, which if violated will result in even more drops to 9.96. On the upside, there is a resistance level at 10.80. A further resistance level may holdings at 11.17. The Relative Strength Index (RSI) on the 14-day chart is 28.97, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.07, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.11%. Stochastics %K at 10.02% indicates the stock is a buying.
How much short interest is there in Rocket Pharmaceuticals Inc?
A steep rise in short interest was recorded in Rocket Pharmaceuticals Inc stocks on 2024-12-31, growing by 2.54 million shares to a total of 12.93 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 10.39 million shares. There was a rise of 19.66%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on October 24, 2023 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $65 price target.
